Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes

Brian D. Green*, Peter R. Flatt, Clifford J. Bailey

*Corresponding author for this work

Research output: Contribution to journalReview article

151 Citations (Scopus)

Abstract

Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPPIV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.

Original languageEnglish
Pages (from-to)159-165
Number of pages7
JournalDiabetes and Vascular Disease Research
Volume3
Issue number3
DOIs
Publication statusPublished - 01 Dec 2006

Keywords

  • Dipeptidyl peptidase IV
  • DPP IV
  • DPP IV inhibition
  • Gliptin
  • Incretin hormones

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this